Ionis EVP sells 26K shares after option exercise

Ionis Pharmaceuticals executive Eugene Schneider reported an exercise-and-sale transaction in company stock.

Rhea-AI Filing Summary

Ionis Pharmaceuticals executive Eugene Schneider reported an exercise-and-sale transaction in company stock. On June 26, 2026, he exercised options to acquire 26,000 shares of common stock at $60.89 per share, then sold 26,000 shares in open-market trades at a weighted-average price of $81.046 per share.

The sales were executed under a pre-arranged Rule 10b5-1 Trading Plan adopted on November 19, 2025. After these transactions, Schneider directly held 77,114 shares of Ionis common stock.

Insider Trade Summary 10b5-1

Exercise and Sale: 26,000 shares ($524K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Schneider Eugene

Role EVP, Chf Clinical Develop Ofcr

Sold 26,000 shs ($2.11M)

Approx. gross sale proceeds $2.11M

Approx. exercise cost $1.58M

Approx. pre-tax spread $524K

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (right to buy)	26,000	$0.00	$0.00
Exercise	Common Stock	26,000	$60.89	$1.58M
Sale	Common Stock	26,000	$81.046	$2.11M

Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 26,000 contracts (Direct); Common Stock — 77,114 shares (Direct)

Footnotes (2)

1. F1. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 19, 2025.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.00 to $81.34 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

Key Figures

Shares sold: 26,000 shares Weighted-average sale price: $81.046 per share Options exercised: 26,000 shares +3 more

6 metrics

Shares sold 26,000 shares Common stock open-market sale on June 26, 2026

Weighted-average sale price $81.046 per share Common stock sales, prices from $81.00 to $81.34

Options exercised 26,000 shares Non-qualified stock option exercise on June 26, 2026

Option exercise price $60.89 per share Conversion or exercise price for 26,000 options

Shares held after transaction 77,114 shares Direct common stock ownership following June 26, 2026 trades

Rule 10b5-1 plan adoption date November 19, 2025 Plan governing the June 26, 2026 share sales

Key Terms

Rule 10b5-1 Trading Plan, Non-Qualified Stock Option (right to buy), weighted average price

3 terms

Rule 10b5-1 Trading Plan regulatory

"Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 19, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Non-Qualified Stock Option (right to buy) financial

"Security title listed as Non-Qualified Stock Option (right to buy) with underlying common stock."

weighted average price financial

"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.00 to $81.34 inclusive."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Ionis Pharmaceuticals (IONS) report for Eugene Schneider?

Ionis EVP Eugene Schneider exercised 26,000 stock options and sold 26,000 common shares. The sale was executed in the open market and reported as part of a combined exercise-and-sale transaction on June 26, 2026 under a pre-arranged Rule 10b5-1 plan.

How many Ionis Pharmaceuticals shares did Eugene Schneider sell and at what price?

Eugene Schneider sold 26,000 Ionis common shares at a weighted-average price of $81.046. The filing notes the trades occurred in multiple transactions within a price range from $81.00 to $81.34, all on June 26, 2026, in open-market sales.

What stock options did Eugene Schneider exercise in the latest Ionis Form 4 filing?

Schneider exercised non-qualified stock options covering 26,000 Ionis common shares at a conversion or exercise price of $60.89 per share. These options were originally exercisable beginning January 2, 2021 and were scheduled to expire on January 1, 2027, according to the filing details.

Were Eugene Schneider’s Ionis Pharmaceuticals share sales made under a Rule 10b5-1 plan?

Yes, the filing states the shares were sold pursuant to a Rule 10b5-1 Trading Plan adopted by Schneider on November 19, 2025. Such plans are pre-arranged trading instructions designed to allow insiders to sell shares over time according to predetermined parameters.

How many Ionis Pharmaceuticals shares does Eugene Schneider hold after the reported transactions?

Following the June 26, 2026 transactions, Schneider directly holds 77,114 shares of Ionis common stock. This post-transaction balance reflects the exercise of 26,000 options, the sale of 26,000 shares in the open market, and the resulting remaining direct equity position reported in the Form 4.

What price range did Ionis EVP Eugene Schneider receive for his sold shares?

The reported weighted-average sale price was $81.046 per share, with individual trades executed between $81.00 and $81.34. The filing notes that detailed trade-level pricing information is available to the company, its security holders, or SEC staff upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/30/2026 - 05:48 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schneider Eugene

(Last) (First) (Middle)

2855 GAZELLE COURT

(Street)

CARLSBAD CALIFORNIA 92010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chf Clinical Develop Ofcr

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/26/2026		M		26,000	A	$60.89	103,114	D
Common Stock	06/26/2026		S		26,000(1)	D	$81.046(2)	77,114	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	$60.89	06/26/2026		M			26,000	01/02/2021	01/01/2027	Common Stock	26,000	$0.0	26,000	D

Explanation of Responses:

1. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 19, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.00 to $81.34 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

	By: Patrick R. O'Neil, attorney-in-fact For: Eugene Schneider	06/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)